Richard Bunt, MD
Psychiatry · Palm Bay, FLNPI 1376619072
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $15,400 of the $23,913 with a category attached, or 64.4%. AbbVie accounts for 75.6% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2019 at $16,927 and has fallen 81.5% since, to $3,134 in 2025. Among psychiatry clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 346 payments — averaging $69.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$18K
- Neurocrine Biosciences, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$527
- Takeda Pharmaceuticals U.S.A., Inc.$399
- Lundbeck LLC$370
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$367
- plus $2K from 20 others
Across 151 payments — averaging $8379.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Supernus Pharmaceuticals, Inc.$631K
- AbbVie$380K
- Alkermes, Inc.$246K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$8K
What the payments were for
- Speaking & faculty fees$15,40064%
- Travel & lodging$2,0639%
- Food & beverage$6,38927%
- Education$600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 177 | $18,072 |
| Neurocrine Biosciences, Inc. | 16 | $2,244 |
| Otsuka America Pharmaceutical, Inc. | 28 | $527 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $399 |
| Lundbeck LLC | 22 | $370 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $367 |
| Sunovion Pharmaceuticals Inc. | 7 | $329 |
| Neuronetics, Inc. | 4 | $248 |
| E.r. Squibb & Sons, L.L.C. | 4 | $205 |
| Vanda Pharmaceuticals Inc. | 10 | $192 |
| Orexo US, Inc. | 10 | $176 |
| Indivior Inc. | 2 | $143 |
| Axsome Therapeutics, Inc. | 6 | $136 |
| Tris Pharma Inc | 6 | $115 |
| Johnson & Johnson | 2 | $100 |
| Avanir Pharmaceuticals, Inc. | 4 | $85 |
| Supernus Pharmaceuticals, Inc. | 3 | $45 |
| Teva Pharmaceuticals USA, Inc. | 1 | $28 |
| Almatica Pharma LLC | 1 | $25 |
| Ironshore Pharmaceuticals Inc. | 1 | $19 |
| Adlon Therapeutics L.p. | 1 | $19 |
| Alkermes, Inc. | 1 | $18 |
| Neos Therapeutics, LP | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| Corium, LLC | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$15,658
- LATUDA$235
- SUBLOCADE$125
- COBENFY$122
- NEUROSTAR TMS THERAPY$104
How this compares
$23,913 in reported general payments places this provider in the 95th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 12 | $17,454 |
| Lurasidone Hcl | 18 | $7,962 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 73 | $6,594 |
| Clozapine | 32 | $4,929 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 87 | $3,417 |
| Bupropion XlBupropion Hcl | 94 | $1,959 |
| Quetiapine Fumarate | 126 | $1,654 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 27 | $1,573 |
| Olanzapine | 35 | $1,114 |
| Eszopiclone | 57 | $1,052 |
| Aripiprazole | 79 | $1,033 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 13 | $1,005 |
| Duloxetine Hcl | 36 | $990 |
| Hydroxyzine Pamoate | 62 | $970 |
| Methylphenidate Hcl | 20 | $921 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $18,072 | $17,45412 claims |
| Almatica Pharma LLCSertraline Hcl | $25 | $49774 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Palm Bay
- James JacobsonPalm Bay$67K
- Andrew CutlerLakewood Ranch$5.7M
- Richard JacksonBoca Raton$3.6M
- Ilan MelnickCoral Gables$2.8M
- Todd BroderSt Augustine$1.6M
- Heather LuingSaint Augustine$1.5M
- Todd GatesWest Melbourne$1.2M
- Lawrence ReccoppaGainesville$968K
- Thomas ValenteLeesburg$967K
- Michelle ScargleClearwater$926K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.